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Purpose: The aim of this study was to evaluate and compare the release of
moxifloxacin from a variety of daily disposable (DD) contact lenses (CLs) under various
conditions using a novel in vitro eye model.
Methods: Four commercially available DD conventional hydrogel (CH) CLs (nelfilcon
A, omafilcon A, etafilcon A, and ocufilcon B) and three silicone hydrogel (SH) CLs
(somofilcon A, narafilcon A, and delefilcon A) were evaluated. These lenses were
incubated in moxifloxacin for 24 hours. The release of the drug was measured using a
novel in vitro model in three experimental conditions: (1) phosphate buffered saline
(PBS); (2) artificial tear solution (ATS) containing a variety of proteins and lipids; and (3)
ATS with mechanical rubbing produced by the device.
Results: Overall, CH CLs had a higher drug release than SH CLs (P , 0.05) under all
conditions. Typically, a higher drug release was observed in PBS than ATS (P , 0.05).
For CH, drug release was found to be higher in ATS with rubbing than PBS or ATS (P,
0.05). For most lens types, ATS with rubbing produced higher drug release than ATS
alone (P , 0.05). Generally, the release kinetics for all conditions were sustained over
the 24-hour testing period, and no burst release was observed (P , 0.05).
Conclusions: Moxifloxacin release from a CL into ATS is lower when compared to
release into PBS. When mechanical rubbing is introduced, the amount of drugs
released is increased.
Translational Relevance: Results suggest that sophisticated in vitro models are
necessary to adequately model on-eye drug release from CL materials.
Introduction
Ocular drug delivery using contact lenses (CLs) is
an interesting concept, and if successful, could change
the paradigm of treating ocular surface diseases. The
conventional treatment of using eye drops is prob-
lematic, and often ineffective, due to precorneal drug
loss through tear dilution,1–3 blinking,4 drainage,1,3
and nonspecific absorption.1,3 Consequently, the
average residence time for most eye drops on the
ocular surface is only 2 to 5 minutes.5 The majority of
the medication is drained into the nasolacrimal duct
and absorbed into the bloodstream,6 which can then
lead to undesirable systemic side effects.
Many of these barriers to ocular surface delivery of
drugs can be overcome by using a CL as the drug
delivering device. Drugs that are released from the CL
into the postlens tear film that sits between the lens
and the cornea have longer precorneal residence
time.7 Thus, in theory, a drug-delivering CL would
improve a treatment regimen by significantly improv-
ing corneal drug absorption and consequently reduc-
ing the dosing frequency and concentration required
to obtain therapeutic levels. The idea of using a CL
for drug delivery dates back to the 1960s,8,9 and
considerable research has been conducted since that
time to develop a viable commercial product.10–15
Unfortunately, despite extensive efforts, there are still
no commercial devices on the market, in part due to a
limited understanding of how these devices would
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perform in vivo, resulting in skepticism on their
potential effectiveness.
In the past, drug-delivering CLs were typically
assessed in vitro using a vial containing 2 to 5 mL of
phosphate buffered saline (PBS).10–13,16–19 This vial-
based model fails to adequately simulate the natural
flow and volume of the tear film environment.20,21 In
a previous study, we showed, using an in vitro eye
model to simulate tear volume and flow, that the
release profile of two antibiotics (ciprofloxacin and
moxifloxacin) from CLs can be sustained for 24
hours.22 These results contrast those obtained from
the same materials in a static vial, where the release
followed the traditional burst-plateau profile for drug
release from CLs.22 These results suggest that the
parameters of the in vitro release system play a
significant role in determining the release kinetics of
drugs from CLs. Thus, to better understand and
assess how CLs release drugs in vivo, the effects of
other key ocular parameters should also be investi-
gated in vitro.
The composition of tear fluid and the mechanical
rubbing produced by the lids are two important
factors that may influence ocular drug delivery. The
composition of the elution solution has been noted
previously to impact the release of phospholipids
from CLs.23 The effects of eye blinking on drug
release from hydrogels has been noted in only one
study.24 To our knowledge, no studies have examined
the combined effects of an artificial tear solution
(ATS) that mimics the composition of the human tear
film and mechanical wear on drug release from CLs.
The aim of this study was to evaluate and compare
the release of moxifloxacin from a variety of daily
disposable (DD) CLs in an ATS when exposed to
mechanical rubbing using a novel in vitro eye model.
Moxifloxacin is an important antimicrobial agent
used in the treatment of a wide range of ocular surface
diseases.25,26
Materials and Methods
CLs and Drug Incubation
Four conventional hydrogel (CH) CLs (nelfilcon A
[Alcon, Fort Worth, TX], omafilcon A [Cooper-
Vision, Pleasanton, CA], etafilcon A [Johnson &
Johnson, New Brunswick, NJ], and ocufilcon B
[CooperVision]) and three silicone hydrogel (SH)
lenses (somofilcon A [CooperVision], narafilcon A
[Johnson & Johnson], and delefilcon A [Alcon]) were
evaluated in this study. All lenses had a dioptric
power of 3.00 with a base curve of 8.6 mm. The
properties of the lenses are detailed in Tables 1 and 2.
Nine lenses of each type were incubated in 1.0 mg/mL
moxifloxacin (Selleckchem, Houston, TX) solution in
PBS (pH 7.4) for 24 hours.
Experimental Setup
The in vitro eye model, Ocuflow, previously
developed in our lab was used in this study to
evaluate the drug release from CLs.22,27–29 The setup
of the eye model with attachment to a microfluidic
system is shown in Figure 1. The humidity was
maintained using a humidifier and hygrometer to a
minimum of 50% air moisture.
After the drug incubation period, the lenses were
partially dried on lens paper and then placed into the
eye model. For all testing conditions, the flow rate of
the fluid that bathed the lens while in the Ocuflow was
set to 2.1 lL/minute (3 mL/24 hours). The flow-
through fluid was collected in a 12-well plate. At the
Table 1. Properties of CHs Used in the Study22
BioMedics
1 Day
1-Day Acuvue
Moist
Proclear
1 Day
Dailies
AquaComfort Plus
United States adopted name
(USAN)
Ocufilcon B Etafilcon A Omafilcon A Nelfilcon A
Manufacturer CooperVision Johnson & Johnson CooperVision Alcon
Water content (%) 52% 58% 60% 69%
FDA group IV IV II II
Centre thickness (mm) 0.07 0.08 0.09 0.10
Oxygen permeability (31011) 16.8 28 33 26
Principal monomers HEMA, PVP, MA HEMA, PVP, MA HEMA, PC PVA, FMA, HPMC, PEG
EGDMA, ethylene glycol dimethacrylate; FMA, N-formylmethyl acrylamide; HPMC, hydroxypropylmethylcellulose; MA,
methacrylic acid; PC, 2-methacryloyloxyethyl phosphorylcholine; PEG, polyethylene glycol; PVP, polyvinyl pyrrolidone.
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specified time intervals, t¼ 0, 1, 2, 3, 4, 5, 6, 7, 8, 12,
16, and 24 hours, 100 lL of this solution was
withdrawn and transferred into a 96-well plate. The
fluorescence of moxifloxacin was measured using the
SpectraMax M5 UV-Vis Spectrophotometer (Molec-
ular Devices, Sunnyvale, CA) at excitation and
emission wavelengths of 296 nm and 471 nm,
respectively.30
The release of moxifloxacin from CLs was tested in
three experimental conditions: (1) PBS, (2) ATS, and
(3) ATS with mechanical rubbing produced by the
device. ATS, containing salts, urea, glucose, proteins,
mucin, and various lipids, was prepared, according to
a method previously reported by our group.31 The
rate of mechanical rubbing was set to 10 rotations/
min, within the average range for blink rates per
minute (4.5–26 blinks/minute).32
Artificial Tear Solution
The composition of the ATS has been previously
reported by our group.31 In brief, it contains various
salts, urea, glucose, proteins (lysozyme and hen egg
albumin), mucin, and various lipids (oleic acid methyl
ester, cholesterol, triolein, phosphatidylcholine, cho-
lesteryl oleate, and oleic acid).31 The viscosity of ATS
was measured at 238C using the Ostwald viscometer
(VWR, Radnor, PA).
Statistical Analysis
Statistical analysis, repeated measures analysis of
variance (RM-ANOVA) and posthoc Tukey’s multi-
ple comparison tests, was performed using Statistica 8
software (StatSoft, Tulsa, OK). Unless otherwise
stated, all data are reported as mean 6 standard
deviation. Statistical significance was considered
significant for a P value of , 0.05.
Results
The total moxifloxacin released after 24 hours
from seven DD CLs are summarized in Table 3 and
Figure 2. The drug release profile over 24 hours for
each experimental condition are shown in Figures 3 to
5. Generally, the drug release from CLs was sustained
over the 24-hour testing period for all conditions, and
no burst release was observed (P , 0.05). Overall,
Table 2. Properties of SHs Used in the Study22
Dailies Total 1
1-Day Acuvue
TruEye
Clariti
1 Day
United States adopted name
(USAN)
delefilcon A narafilcon A somofilcon A
Manufacturer Alcon Johnson & Johnson CooperVision
Water content (%) 33%
(surface .80%)
46% 56%
FDA group V V V
Centre thickness (mm) 0.09 0.09 0.07
Oxygen permeability (31011) 140 100 60
Oxygen transmissibility (3109) 156.0 118.0 86
Principal monomers Not disclosed MPMDSM, DMA, HEMA,
siloxane macromer,
TEGDMA, PVP
Not
disclosed
DMA, N,N-dimethylacrylamide; MPDMS, monofunctional polydimethylsiloxane; PVP, polyvinyl pyrrolidone; TEGDMA,
tetraethyleneglycol dimethacrylate.
Figure 1. In vitro eye model (Ocuflow) setup: (A) corneal
eyepiece and lid; (B) 12-well collecting plate; (C) rotational
motion to create rubbing motion; (D) inlet for ATS tear flow.
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conventional hydroxyethyl methacrylate (HEMA)-
based hydrogel CLs had a higher drug release than
SH CLs (P , 0.05) under all conditions (P , 0.001).
Typically, a higher drug release was observed in
PBS than ATS (P , 0.05). For CH CLs, drug release
was found to be higher in ATS with rubbing than PBS
or ATS (P , 0.05). For most lens types, ATS with
rubbing produced higher drug release than ATS alone
(P , 0.05). Total drug release in PBS varied between
27.9 6 4.0 and 111.3 6 12.9 lg/lens, in ATS drug
release ranged between 7.0 6 3.2 and 96.2 6 4.4 lg/
lens, and in ATS with rubbing the drug release ranged
between 18.1 6 4.3 and 164.3 6 15.5 lg/lens.
To determine the components in ATS that may
have led to a reduction in the observed drug release, a
subsequent experiment was conducted with 2 CH
(etafilcon A and ocufilcon B) and 1 SH (somofilcon
A) in either ATS without proteins or ATS without
lipids (P , 0.05). As shown in Figure 6, there were no
differences for drug release from somofilcon A
between the three tested solutions. For etafilcon A
and ocufilcon B, there were differences in total drug
release between the three solutions (P , 0.05), but
there was no conclusive trend. The dynamic viscosity
of the ATS was 1.09 6 0.03 mPas, which was slightly
higher than the viscosity of PBS 0.99 6 0.01 mPas at
238C (P , 0.001). The measured viscosity for PBS is
similar to the reported viscosity of water.33
Overall, materials that released the highest
amounts of moxifloxacin were etafilcon A (1-Day
Acuvue Moist) and ocufilcon B (Biomedics 1 Day),
which are both HEMA-based, Food and Drug
Administration (FDA) group IV materials with a
high water content and are negatively charged.
Omafilcon A (Proclear 1 Day), a HEMA-based,
FDA group II material with a high water content
but overall neutral charge, also showed high drug
release. The CLs releasing the lowest amount of drug
for each testing condition were nelfilcon A (Dailies
AquaComfort Plus), a polyvinyl alcohol (PVA)-
based, FDA group II material with a high water
content and neutral charge, as well as all SH lenses.
All lenses containing moxifloxacin were visually clear
throughout the entire duration of the study.
Table 3. Release (lg/lens) Moxifloxacin after 24 Hours from CH and SH DD CLs in PBS, ATS, and ATS with
Mechanical Rubbing
Commercial Name Material
Moxifloxacin
in PBS (lg/lens)
Moxifloxacin
in ATS (lg/lens)
Moxifloxacin in ATS
þ Rubbing (lg/lens)
CH1-Day Acuvue Moist etafilcon A 111.26 6 12.9 96.2 6 4.4 164.3 6 15.5
CHBiomedics 1 Day ocufilcon B 107.5 6 23.4 62.9 6 9.9 158.8 6 24.4
CHProclear 1 Day omafilcon A 95.0 6 6.2 75.9 6 7.7 108.4 6 21.8
CHDailies Aqua Comfort Plus nelfilcon A 45.1 6 3.6 24.0 6 3.6 40.42 6 2.6
SHClariti 1 Day somofilcon A 42.4 6 5.1 28.0 6 3.7 30.6 6 11.3
SHDailies Total 1 delefilcon A 27.9 6 3.9 16.7 6 3.7 18.07 6 4.3
SH1-Day Acuvue TruEye narafilcon A 30.2 6 0.8 7.0 6 3.2 28.7 6 6.6
Figure 2. Total release of moxifloxacin (lg/lens) from DD commercial CLs in PBS, ATS, and ATS with mechanical rubbing. The values
plotted are the mean 6 standard deviation for three trials.
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Discussion
The rate of drug release into an aqueous media is
determined by its solubility, and the rate at which the
drug reaches equilibrium between the solution and the
lens. The release of moxifloxacin, which is highly
hydrophilic,34 would therefore be dependent on the
rate of tear flow. In a previous study measuring the
release of moxifloxacin from the same eye model,
drug release from CLs was sustained for 24 hours for
etafilcon A and ocufilcon B.22 Omafilcon A reached a
plateau within 12 hours, while narafilcon A and all
SHs released moxifloxacin within 4 hours.22 In the
previous study, the flow rate was set at 3.33 lL/
minute (4.8 mL/day). However, in this study, the flow
Figure 4. Release of moxifloxacin (lg/lens) in the eye model with a flow rate of 2.1 lL/minute ATS over 24 hours. The values plotted are
the mean 6 standard deviation for three trials.
Figure 3. Release of moxifloxacin (lg/lens) in the eye model with a flow rate of 2.1 lL/minute PBS over 24 hours. The values plotted are
the mean 6 standard deviation for three trials.
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rate was decreased to 2.08 lL/minute (3.0 mL/day),
closer to physiological tear turnover rates,21 and the
release of moxifloxacin from CLs into PBS was
sustained over the 24 hours for all lens types (P ,
0.05). In a vial, the release of moxifloxacin follows
more closely to a burst-plateau profile within 1
hour.22
Considering the prominent roles of proteins and
lipids in the fouling of CLs,35,36 using PBS as an
elution solvent potentially overlooks key determi-
nants in drug release. The effect of the composition of
the release medium on therapeutics release from CLs
has been previously reported; the release of phospho-
lipids from CLs were five times faster in ATS than
water.23 Surprisingly, in this study the release of
moxifloxacin was significantly lower when released in
ATS than PBS (P , 0.05), which markedly contrasts
previous published results.23 The differences in the
observed release could be attributed to the differences
in properties between phospholipids and moxiflox-
Figure 6. Release of moxifloxacin (lg/lens) in a lipid solution, protein solution, and ATS. The values plotted are the mean 6 standard
deviation for three trials.
Figure 5. Release of moxifloxacin (lg/lens) in the eye model with a flow rate of 2.1 lL/minute ATS and mechanical rubbing over 24
hours. Mechanical rubbing was set to 10 rotations/minute. The values plotted are the mean 6 standard deviation for three trials.
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acin, the composition of ATS, and the in vitro model
used to measure the release. Nevertheless, the
underlying mechanisms resulting in a lower drug
release in ATS than a PBS solution is unclear.
Drug release from CLs into ATS is significantly
more complex to describe than PBS due to the
presence of various salts, proteins, mucin, and lipids
within ATS.31 Any one of these factors, or a
combination of them, could interact with the drug
in the lens, leading to a lower or higher drug release.
Furthermore, the mechanisms of protein and lipid
deposition on the CLs37 could also alter drug–lens
interactions, and consequently drug release kinetics.
However, the duration of the experiment was only 24
hours, and within this time frame it is expected that
tear film deposition would not have a significant
impact on drug release.
To elucidate the individual effects of proteins and
lipids on drug release, three lenses (etafilcon A,
somofilcon A, and ocufilcon A) were tested in ATS
without either proteins or lipids. For somofilcon A,
there were no differences in the amount of moxiflox-
acin release in ATS, ATS without proteins, or ATS
without lipids (P . 0.05). For etafilcon A, ATS
without proteins released less drug than ATS (P ,
0.05), while for ocufilcon A, ATS without lipids
released less drug than ATS (P , 0.05). These results
suggest that each lens material interacts differently
with ATS, resulting in slightly different drug release
kinetics. Currently, there is no obvious trend to
explain for the effects of protein or lipids on drug
release from CLs.
Another explanation for a lower drug release from
CLs is the differences in viscosity between PBS and
ATS. The dissolution of a drug into the media is
dependent on the media viscosity, where higher
viscosity leads to slower drug dissolution.38 However,
the viscosity of ATS is only slightly higher than that
of PBS. So while the higher viscosity of ATS may
contribute to the lower drug release, it is likely that it
is not the primary factor leading to the observed
trend. The viscosity of ATS in this study is lower than
the viscosity of human tears (2.33 mPas).33 This is
likely due to the fact that our ATS does not contain
many of the lipids that contribute to the viscosity of
natural tears.33
Another important ocular parameter that can
affect drug release from CLs is blinking. In this
study, only the mechanical wear component of the
blink was simulated. The CL sits tightly between the
corneal eyepiece and eyelid piece. The rotation of the
corneal eyepiece circularly causes the CL to rub
against the eyelid piece. The rubbing occurred at a
rate of 10 cycles every minute, which falls within the
average range for blink rates, of 4.5 to 26 blinks/
minute.32 For most lens types, mechanical rubbing in
ATS resulted in significantly higher drug release than
ATS alone (P , 0.05). This observation also has been
reported in another study modelling the effects of
blinking on drug release from hydrogels.24 Further-
more, the tear film is shear-thinning (non-Newtonian)
in which the viscosity is not constant. We speculate
that the rubbing process between the eyelid and
corneal eyepiece decreases the viscosity of the
ATS,33,39 which increases the amount of drugs
released from the CL.
In general, CH lenses released more drugs than SH
lenses, which is similar to previously reported
results.10,16,22 Etafilcon A (1-Day Acuvue Moist)
and ocufilcon B (Biomedics 1 Day), two CH materials
with a high water content that are negatively charged,
released the highest amount of moxifloxacin. Nelfil-
con A (Dailies AquaComfort Plus) was the only CH
that behaved like a SH in regards to drug release. The
lowered drug release for this lens type is unclear, but
could be linked to the composition of the material,
which is composed of PVA instead of the traditional
HEMA-based materials found in other CH. Further-
more, the lens also contains wetting agents such as
PVA and PEG, which are not cross-linked to the
polymer. These agents occupy space within the
matrix, which could interfere with the lens ability to
absorb and release drugs. The two lenses with the
lowest drug release for all tested conditions were two
SH, delefilcon A (Dailies Total 1) and narafilcon A
(1-Day Acuvue TruEye).
An important concern in CL drug delivery is
whether the amount of drugs released by the CL is
comparable to eye drops for treatment. In general, the
amount of drugs that can be loaded and released from
a CL is significantly lower in comparison to the
amount in eye drops administered over the treatment
duration. That being said, the idea behind drug
delivery with CL is to achieve similar or better
efficacy than eye drops at lower drug dosing. Results
from several in vivo studies have validated the efficacy
a CL drug delivery platform, despite releasing
considerably less drugs.15,40–45 For in vitro studies,
the minimum inhibitory concentrations for 90% of
bacterial isolates (MIC90) can be used as relative
measure of efficacy for release of antibiotics. All of
the CLs, in all testing conditions, released enough
moxifloxacin to meet the MIC90 (0.047 lg/mL)
46
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against common and susceptible pathogens over the
24-hour study period.
Based on the in vitro model used in this study, the
release of moxifloxacin can be sustained for up to 24
hours. The drug release profiles are dependent on the
properties of the CL. The amount of drug that is
released is dependent on the composition of the
elution solution, with lower amounts of drug being
released in ATS than PBS. When mechanical rubbing
is introduced to those lenses exposed to ATS, the
amount of drug released from the CLs increased
compared to ATS alone. In conclusion, certain
parameters such as ATS can decrease the amount of
drugs released, while other parameters, such as
mechanical rubbing, increases the amount of drugs
released. These results underline the importance of
considering various ocular parameters when deter-
mining drug release from CLs. Another key param-
eter affecting drug release from CLs, the properties of
the drug such as molecular size, chemical structure,
polarity, and solubility,47,48 was not investigated in
this study. This factor, and the complex interactions
between material, drug properties, and elution system
on CL drug delivery will be investigated in future
studies.
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